Heidelberg Pharma AG · XETR:HPHA
Heidelberg Pharma — Deutsche Biotechnologietage 2023
20 slides from Heidelberg Pharma's conference presentation, Mar 28, 2023
Slide 1: ATACs: A Unique New Mode of Action to Fight Cancer
ATACs: A Unique New Mode of Action to Fight Cancer Deutsche Biotechnologietage - 28th March 2023
Slide 2: Safe Harbor
Safe Harbor Forward looking statements This communication contains certain forward-looking statements, relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or sim
Slide 3: Heidelberg Pharma – a Clinical Stage Company
Heidelberg Pharma – a Clinical Stage Company Our Our Approach Company Inhibition of RNA Polymerase II ~ 110 employees Targeted delivery via antibodies (ADC technology) Use Amanitin as toxic payload (ATAC technology) Headquarters in Heidelberg area, Germany Listed on Frankfurt Stock Exchange: HPHA Ou
Slide 4: Growing Pipeline of Proprietary and Partnered Programs
Growing Pipeline of Proprietary and Partnered Programs Product Target Indication Research Preclinic Phase I Phase II Phase III Partner HDP-101 BCMA Multiple Myeloma (DBCL/CLL) Huadong (Asia) ATAC pipeline HDP-102 CD37 NHL Huadong (Asia, option) HDP-103 PSMA Prostate cancer Huadong (Asia) HDP-104 GCC
Slide 5: ATAC Technology & Proprietary Projects
ATAC Technology & Proprietary Projects 5
Slide 6: ATACs: ADCs with Amanitin as a Payload
ATACs: ADCs with Amanitin as a Payload Antibody • Targeting tumor antigen Amanitin as Warhead • Differentiated mechanism of action: inhibition of RNA Polymerase • Kills dormant tumor cells • Overcomes resistance • Predictive biomarker • Synthetic amanitin derivatives with improved properties • GMP m
Slide 7: The Payload Makes The Difference
The Payload Makes The Difference Amatoxins – a novel mode of action in oncology Group of toxins from the poisonous Amanita phalloides Murine breast cancer xenograft model green death cap mushroom 1000 (Amanita phalloides) Mean tumore volume [mm3] • Same antibody (Trastuzumab), different 500 payload
Slide 8: ATACs Promise Higher Efficacy in Certain Aggressive Tumors
ATACs Promise Higher Efficacy in Certain Aggressive Tumors del(17p) as a potential biomarker for higher ATAC sensitivity • Chromosomal deletion that eliminates p53 (higher-risk tumor) Collaboration with MD Anderson: and frequently POL2RA gene: Higher ATAC sensitivity of del(17p) myeloma cells lower
Slide 9: ATACs Promise Significant Clinical Benefits
ATACs Promise Significant Clinical Benefits Unique preclinical features of HDP-101 Potential clinical benefit Efficacious against dormant tumor cells Longer PFS and MRD negativity Efficacious in ultra-low target-expressing tumor cells Deeper responses and higher ORR Novel MoA to which all patients w
Slide 10: Lead Program: HDP-101 in Multiple Myeloma
Lead Program: HDP-101 in Multiple Myeloma Multiple Myeloma (MM) HDP-101: Anti-BCMA-ATAC • 70,000 deaths annually • Targeted elimination of BCMA-containing • Median survival ~47-110 months cells with favorable preclinical toxicity profile • Characterized by the proliferation of single clone of plasma
Slide 11: First-in-Human Clinical Trial with an ATAC ongoing
First-in-Human Clinical Trial with an ATAC ongoing HDP-101: anti-BCMA-ATAC for multiple myeloma Two-part, open-label, multicenter Phase I/IIa study to determine safe dose and assess preliminary efficacy 2022 2023 2024 2025 Dose for Phase IIa Expansion cohorts FPI Dose escalation in MM patients: up t
Slide 12: Further ATAC Candidates: HDP-102, HDP-103 and HDP-104
Further ATAC Candidates: HDP-102, HDP-103 and HDP-104 HDP-102: anti-CD37-ATAC HDP-104: anti-GCC-ATAC • CD37 is overexpressed on B-cell lymphoma cells • Guanylyl cyclase C (GCC) is a transmembrane receptor protein • Specific indication of non-Hodgkin lymphoma (NHL) (GUCY2C) for regulation of intestin
Slide 13: Partner Projects & Next Steps
Partner Projects & Next Steps 13
Slide 14: Partner Projects
Partner Projects Strategic partnership with Huadong Medicine (February/September 2022) Exclusive licensing agreement for Asia* • Exclusive development and commercialization rights for HDP-101 and HDP-103; deal value: up to USD 469 m + royalties • Exclusive option for HDP-102 and HDP-104; deal value:
Slide 15: Highlights 2022 - Legacy Portfolio: Partner Telix
Highlights 2022 - Legacy Portfolio: Partner Telix - Progressing towards Filing for Market Approval Pivotal Phase III ZIRCON reported positive topline results with imaging agent TLX250-CDx in November 2022 Accurate diagnosis of clear cell renal cell carcinoma (ccRCC) with TLX250-CDx (89Zr-DFO-girentu
Slide 16: Financials & Outlook
Financials & Outlook 16
Slide 17: Financials and Shareholdings
Financials and Shareholdings Corporate bodies 2022 5% Freefloat • Sales revenue significantly higher due to upfront payment by Huadong 14% • Huadong became 2nd largest shareholder, dievini remains largest shareholder Dietmar Hopp and • Operating expenses including depreciation and amortization incre
Slide 18: Next Steps Proprietary ATAC Pipeline
Next Steps Proprietary ATAC Pipeline High priority and focus on HDP-101 to advance validation HDP-101 HDP-102 Phase I/IIa study in RRMM CD37-ATAC for NHL • Dose escalation ongoing, further study centers in Poland and Hungary • Completion of preclinical and toxicological studies • Implementation of a
Slide 19: Investment Summary
Investment Summary A clinical-stage company with the goal of becoming a global ADC player Disruptive first-in-humans mode of action provides high Validated by international efficacy and potential for unique high-quality partnerships clinical advantages Clinical lead program with Increased efficacy a
Slide 20: Heidelberg Pharma AG Q & A
Heidelberg Pharma AG Ladenburg, Germany Q&A Tel.: +49 6203 1009 0 investors@hdpharma.com www.heidelberg-pharma.com 20